CYT 150
Alternative Names: CYT-150Latest Information Update: 28 May 2026
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer; Solid tumours
- Discontinued Haematological malignancies
Most Recent Events
- 28 May 2026 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
- 28 May 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 11 Nov 2022 Cytovia intends to submit IND application for CYT 150 and CYT 303 in Liver cancer in 2024 (Cytovia Therapeutics pipeline, November 2022)